We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.20 | -0.01% | 1,705.00 | 1,705.20 | 1,705.60 | 1,709.60 | 1,699.40 | 1,701.60 | 1,078,802 | 13:04:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.25 | 70.24B |
By Dominic Chopping
Danish pharmaceutical company Genmab A/S (GEN.KO) said Wednesday that net sales of leukemia drug Arzerra (ofatumumab) during the second quarter of 2014 were GBP12.8 million.
This figure consists of net sales in the US of GBP6.9 million and in the rest of the world of GBP5.9 million.
Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately DKK23 million.
The second quarter net sales did not include sales related to the supply of ofatumumab for clinical trials run by other parties.
-Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter: @WSJNordics
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions